Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Completed Phase 1Phase 2 Interventional

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260
View directory record Official record
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 19, 2026, 11:16 AM EDT
Withdrawn Phase 2 Interventional

Pilot Study for Locally Advanced Head and Neck Cancer

NCT01262859
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

NCT00819780
View directory record Official record
Conditions
Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
Interventions
Panitumumab, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 19, 2026, 11:16 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 19, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional

Mobile Health Program for Post-Preeclampsia Hypertension

NCT07599579
View directory record Official record
Conditions
Hypertension (HTN), Preeclampsia, Hypertensive Disorders of Pregnancy (HDP)
Interventions
Coaching application, Home-based blood pressure monitoring, WebMD
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 11:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Immediate Postpartum Glucose Tolerance Testing

NCT04199676
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glucose tolerance test
Diagnostic Test
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 19, 2026, 11:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

NCT03251924
View directory record Official record
Conditions
Cancer, Tumors, Neoplasm, Malignancy
Interventions
BMS-986226, Nivolumab, Ipilimumab, Tetanus Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 19, 2026, 11:16 AM EDT
Terminated Phase 2 Interventional Results available

Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

NCT00285779
View directory record Official record
Conditions
Lichen Planus
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 19, 2026, 11:16 AM EDT
Completed No phase listed Observational

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

NCT04200378
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915
View directory record Official record
Conditions
Primary Immune Deficiency Disorders (PIDD)
Interventions
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 19, 2026, 11:16 AM EDT
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Phase 1Phase 2 Interventional

Scotoma Reduction in AMD Patients Treated With Ranibizumab

NCT00467935
View directory record Official record
Conditions
Macular Degeneration
Interventions
intravitreal injection Lucentis (ranibizumab)
Drug
Lead sponsor
Retina Research Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Slingerlands, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 19, 2026, 11:16 AM EDT
No Longer Available No phase listed Expanded access

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

NCT01196208
View directory record Official record
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 19, 2026, 11:16 AM EDT
Recruiting Phase 1 Interventional

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
HLX13, Yervoy, OPDIVO
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Glendale, California • Jacksonville, Florida • Margate, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 11:16 AM EDT
Not yet recruiting Phase 3 Interventional

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574
View directory record Official record
Conditions
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions
iSCIB1+, Nivolumab & Ipilimumab, Placebo
Biological · Drug · Other
Lead sponsor
Scancell Ltd
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 11:16 AM EDT
Completed No phase listed Observational

Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

NCT01546324
View directory record Official record
Conditions
Pregnancy Following IVF With PGS/PGD
Interventions
Blood draw
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 19, 2026, 11:16 AM EDT
Terminated Not applicable Interventional

A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

NCT00000824
View directory record Official record
Conditions
HIV Infections
Interventions
Lymphocytes, Activated
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 19, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients

NCT00094068
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Maximizing Acute Kidney Injury End-point Intervention Post-Discharge (MAKE-IT) Study

NCT04358874
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Medication reconciliation, Blood Pressure Management
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 19, 2026, 11:16 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

NCT04120610
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
FlowMet-R, ABI, TBI
Diagnostic Test
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
40 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Des Moines, Iowa • Chesterfield, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 19, 2026, 11:16 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882
View directory record Official record
Conditions
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 11:16 AM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 11:16 AM EDT